Wedbush lowered the firm’s price target on Solid Biosciences (SLDB) to $17 from $18 on higher share count, while keeping an Outperform rating on the shares. The firm says the most important in the company’s update was that all key development timelines remain on track. Solid Biosciences continues to anticipate making an FDA meeting request this summer to discuss SGT-003 accelerated approval pathway options and plans to complete dosing in by 20 subjects by Q4 2025. All in, Wedbush remains impressed by the early INSPIRE data and sees limited credit being assigned at present levels.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SLDB:
- Solid Biosciences: Promising Gene Therapy Advancements and Strategic Initiatives Drive Buy Rating
- Solid Biosciences price target lowered to $17 from $20 at Piper Sandler
- Solid Biosciences price target lowered to $10 from $15 at Barclays
- Solid Biosciences: Promising Developments and Potential Growth in Duchenne Muscular Dystrophy Treatment
- Solid Biosciences Files Prospectus for $85 Million Offering
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue